XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program
18 April 2017 - 9:00PM
XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and
development of therapeutic antibodies, announced today the
presentation of positive data from pre-clinical studies
investigating the activity of its anti-PTH1R antagonist monoclonal
antibody (mAb). The antibody is a potential first-in-class
therapeutic agent for the treatment of hyperparathyroidism (HPT)
and humoral hypercalcemia of malignancy (HHM). These presentations
were made at the American Association for Cancer Research (AACR)
and the Endocrine Society (ENDO) annual meetings.
The PTH1R receptor is part of the B GPCR family and is the
primary receptor of two ligands, parathyroid hormone (PTH) and
parathyroid related protein (PTHrP). Hypercalcemia can occur when
elevated levels of PTH, as seen in primary HPT, or elevated levels
of PTHrP, as seen in HHM, lead to excessive activation of the PTH1R
receptor. A potent and long-acting receptor antagonist could
reverse hypercalcemia in all these conditions.
“Consistent with our new strategy, we are seeking partners with
a deep commitment to and an expertise in drug development who are
interested in licensing this first-in-class antibody and taking it
through the clinical development process,” said Jim Neal, Chief
Executive Officer of XOMA. “There is a real need for better
therapies that address hypercalcemia induced by
hyperparathyroidism, and we are encouraged by these data, which
demonstrate the efficacy of our anti-PTH1R approach as a potential
treatment for patients suffering from HPT and HHM.”
Data presented at the AACR and ENDO conferences between April
1-4, 2017 showed:
- PTH1R antagonism in vitro by the anti-PTH1R mAb translated to
potent in vivo activity
- XOMA’s anti-PTH1R antagonist mAb has the potential to become a
first-in-class therapy for HHM, as the data demonstrated it
ameliorated hypercalcemia and associated morbidities in
pre-clinical models
- XOMA’s antibody libraries enabled the discovery of functional
antibodies against a very complex target – i.e. the G-Protein
Coupled PTH1Receptor
- A high affinity fully human mAb to PTH1R has been selected and
characterized
- Proprietary antibody engineering resulted in antibodies with
improved potency and manufacturing characteristics
“While hyperparathyroidism is a classic endocrine disorder, HHM
spans both endocrine and oncology specialties. HHM is a
life-threatening complication of many advanced cancers and is
caused by tumor secretion of the PTH1R ligand, PTH-related peptide,
which causes high calcium. Since current treatments often fall
short of correcting hypercalcemia and many cancer patients die from
such high calcium and associated metabolic complications, PTH1R
antibodies could prove beneficial for the treatment of this
devastating condition,” said John Wysolmerski, MD, Professor of
Medicine and Associate Section Chief for Research in the Section of
Endocrinology and Metabolism, Yale School of Medicine.
The complete presentations can be found online at
www.xoma.com/content/pipeline/publications.htm.
About XOMA's PTH1R Monoclonal Antibodies
ProgramXOMA has developed unique functional antibody
antagonists targeting PTH1R, a G-protein-coupled receptor involved
in the regulation of calcium metabolism. These antibodies have
shown promising efficacy in in vivo studies and potentially could
address high unmet medical needs, including primary
hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy
(HHM). Some secondary and tertiary HPT cases are additionally
challenging to manage via current pharmacological approaches and
may be well-addressed by XOMA’s anti-PTH1R antibody.
About XOMA CorporationXOMA has an extensive
portfolio of products, programs, and technologies that are the
subject of licenses the Company has in place with other biotech and
pharmaceutical companies. Many of these licenses are the
result of the Company's pioneering efforts in the discovery and
development of antibody therapeutics. There are more than 20
such programs that are fully funded by partners and could produce
milestone payments and royalty payments in the future. To maximize
its value in a licensing transaction, XOMA continues to invest in
X358, an allosteric monoclonal antibody that reduces insulin
receptor activity, as the antibody could be a potential treatment
for hyperinsulinism. For more information, visit www.xoma.com.
Forward-Looking StatementsCertain statements
contained in this press release are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including
statements regarding: the potential for XOMA’s anti-PTH1R
antagonist monoclonal antibody; the potential of XOMA's portfolio
of partnered programs and licensed technologies generating
milestone and royalty proceeds over time; and statements that
otherwise relate to future periods. These statements are based on
assumptions that may not prove accurate, and actual results could
differ materially from those anticipated due to certain risks
inherent in the biotechnology industry and for companies engaged in
the development of new products in a regulated market. Potential
risks to XOMA meeting these expectations are described in more
detail in XOMA's most recent filing on Form 10-K and in other SEC
filings. Consider such risks carefully when considering XOMA's
prospects. Any forward-looking statement in this press release
represents XOMA's views only as of the date of this press release
and should not be relied upon as representing its views as of any
subsequent date. XOMA disclaims any obligation to update any
forward-looking statement, except as required by applicable
law.
Investor contact:
Luke Heagle
Pure Communications
+1 910-726-1372
lheagle@purecommunications.com
Media contact:
Colin Sanford
Pure Communications
+1 415-946-1094
csanford@purecommunications.com
XOMA Royalty (NASDAQ:XOMA)
Historical Stock Chart
From Aug 2024 to Sep 2024
XOMA Royalty (NASDAQ:XOMA)
Historical Stock Chart
From Sep 2023 to Sep 2024